Goldman Sachs
ECYT

Goldman Sachs’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Goldman Sachs’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-85,300
Closed -$562K – 7363
2014
Q2 		$562K Sell
85,300
-19,000
-18% -$214K ﹤0.01% 5202
2014
Q1 		$2.48M Buy
+104,300
New +$1.51M ﹤0.01% 3774

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Goldman Sachs's ECYT Position: Q4 2018 in Review

Goldman Sachs sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 183,678 shares — an estimated $3.26M sold.

Goldman Sachs first reported a position in ECYT in Q2 2013 and held it in 21 quarters. The position peaked at $3.32M in Q1 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Goldman Sachs reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 183,678 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $3.26M.
  • Goldman Sachs first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 21 quarters.
  • Goldman Sachs's Endocyte, Inc. Common Stock position peaked at $3.32M in Q1 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.